BR112021023607A2 - Derivados de pirrolo[2,3-b]piridina e pirazolo[3,4-b]piridina substituídos por inibidores de proteína quinase - Google Patents

Derivados de pirrolo[2,3-b]piridina e pirazolo[3,4-b]piridina substituídos por inibidores de proteína quinase

Info

Publication number
BR112021023607A2
BR112021023607A2 BR112021023607A BR112021023607A BR112021023607A2 BR 112021023607 A2 BR112021023607 A2 BR 112021023607A2 BR 112021023607 A BR112021023607 A BR 112021023607A BR 112021023607 A BR112021023607 A BR 112021023607A BR 112021023607 A2 BR112021023607 A2 BR 112021023607A2
Authority
BR
Brazil
Prior art keywords
pyridine
pyrazolo
pyrrolo
protein kinase
kinase inhibitors
Prior art date
Application number
BR112021023607A
Other languages
English (en)
Inventor
Bin Liu
Chenglin Zhou
Haohan Tan
Kai Yu
Lihua Jiang
Qihong Liu
Shu Lin
Tongshuang Li
Weibo Wang
Weipeng Zhang
Xianlong Wang
Xingdong Zhao
Yanxin Liu
Yunling Wang
Yuwei Gao
Zhifu Li
Zongyao Zou
Zuwen Zhou
Original Assignee
Fochon Pharmaceuticals Ltd
Shanghai Fochon Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fochon Pharmaceuticals Ltd, Shanghai Fochon Pharmaceutical Co Ltd filed Critical Fochon Pharmaceuticals Ltd
Publication of BR112021023607A2 publication Critical patent/BR112021023607A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

derivados de pirrolo[2,3-b]piridina e pirazolo[3,4-b]piridina substituídos por inibidores de proteína quinase. a presente invenção refere-se a certos inibidores de btk, composições farmacêuticas dos mesmos e métodos de uso dos mesmos.
BR112021023607A 2019-05-31 2020-06-01 Derivados de pirrolo[2,3-b]piridina e pirazolo[3,4-b]piridina substituídos por inibidores de proteína quinase BR112021023607A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962854983P 2019-05-31 2019-05-31
US201962904611P 2019-09-23 2019-09-23
US201962935091P 2019-11-14 2019-11-14
PCT/CN2020/093734 WO2020239124A1 (en) 2019-05-31 2020-06-01 SUBSTITUTED PYRROLO [2, 3-b] PYRIDINE AND PYRAZOLO [3, 4-b] PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS

Publications (1)

Publication Number Publication Date
BR112021023607A2 true BR112021023607A2 (pt) 2022-01-04

Family

ID=73553523

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021023607A BR112021023607A2 (pt) 2019-05-31 2020-06-01 Derivados de pirrolo[2,3-b]piridina e pirazolo[3,4-b]piridina substituídos por inibidores de proteína quinase

Country Status (10)

Country Link
US (1) US20220235049A1 (pt)
EP (1) EP3976607A4 (pt)
JP (1) JP2022534715A (pt)
KR (1) KR20220016090A (pt)
CN (1) CN114008042B (pt)
AU (1) AU2020283597A1 (pt)
BR (1) BR112021023607A2 (pt)
CA (1) CA3137985A1 (pt)
MX (1) MX2021014674A (pt)
WO (1) WO2020239124A1 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230110286A (ko) * 2020-11-17 2023-07-21 포천 바이오사이언시스, 리미티드 단백질 키나제 억제제로서 치환된 피롤로 [2,3-b] 피리딘 및 피라졸로 [3,4-b] 피리딘 유도체
EP4234558A1 (en) * 2020-12-07 2023-08-30 Zhejiang Longcharm Bio-Tech Pharma. Co., Ltd. Pyrrolopyridine compound and application thereof
CN112574200B (zh) * 2021-02-26 2021-06-11 安润医药科技（苏州）有限公司 Btk和/或btk的突变体c481s的小分子抑制剂
CN115028633B (zh) * 2021-03-08 2023-12-22 药雅科技(上海)有限公司 吡咯并嘧啶类化合物的制备及其应用
CN113979891A (zh) * 2021-11-08 2022-01-28 上海高准医药有限公司 一种克立硼罗及其中间产物的制备方法
WO2023110970A1 (en) 2021-12-14 2023-06-22 Netherlands Translational Research Center Holding B.V Macrocyclic btk inhibitors
CN114409654A (zh) * 2021-12-30 2022-04-29 安徽普利药业有限公司 一种btk抑制剂的中间体合成方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1696920E (pt) * 2003-12-19 2015-01-14 Plexxikon Inc Compostos e métodos para o desenvolvimento de moduladores de ret
MY153898A (en) * 2005-06-22 2015-04-15 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
AU2010321883A1 (en) * 2009-11-18 2012-05-31 Plexxikon, Inc. Compounds and methods for kinase modulation, and indications therefor
BR112015028845A2 (pt) * 2013-05-30 2017-07-25 Plexxikon Inc compostos para a modulação da quinase e indicações da mesma
WO2018039310A1 (en) * 2016-08-24 2018-03-01 Arqule, Inc. Amino-pyrrolopyrimidinone compounds and methods of use thereof
EP3823968A1 (en) * 2018-07-16 2021-05-26 HepaRegeniX GmbH Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
CN112608318B (zh) * 2019-12-16 2023-09-08 成都海博为药业有限公司 一种作为蛋白质激酶抑制剂的化合物及其用途

Also Published As

Publication number Publication date
EP3976607A1 (en) 2022-04-06
KR20220016090A (ko) 2022-02-08
CN114008042A (zh) 2022-02-01
MX2021014674A (es) 2022-01-11
AU2020283597A1 (en) 2021-11-25
CA3137985A1 (en) 2020-12-03
US20220235049A1 (en) 2022-07-28
EP3976607A4 (en) 2023-07-19
WO2020239124A1 (en) 2020-12-03
CN114008042B (zh) 2023-10-03
JP2022534715A (ja) 2022-08-03

Similar Documents

Publication Publication Date Title
BR112021023607A2 (pt) Derivados de pirrolo[2,3-b]piridina e pirazolo[3,4-b]piridina substituídos por inibidores de proteína quinase
EA201791692A1 (ru) 4H-ПИРРОЛО[3,2-c]ПИРИДИН-4-ОНОВЫЕ ПРОИЗВОДНЫЕ
EA201990048A1 (ru) [1,2,4]ТРИАЗОЛО[1,5-a]ПИРИДИНИЛ-ЗАМЕЩЕННЫЕ ИНДОЛЬНЫЕ СОЕДИНЕНИЯ
WO2017108723A3 (en) PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS
CY1119588T1 (el) Εκλεκτικοι αναστολεις pi3κ δελτα
EA201400701A1 (ru) Замещенные соединения пиразоло[1,5-a]пиридина в качестве ингибиторов тропомиозинрецепторной киназы (trk)
CL2015002303A1 (es) Derivados de pirrolo[2,3-d]pirimidina
BR112016024626A8 (pt) compostos 1h-pirrolo[2,3-c]piridin-7(6h)-onas e pirazolo[3,4-c]piridin-7(6h)-onas, uso dos mesmos, composição farmacêutica que os compreende e método de inibição de uma proteína bet
UY36265A (es) “derivados de pirrolo[2,3-d]pirimidina”.
PH12015502459A1 (en) 2,2-difluoropropionamide derivatives of bardoxolone methyl, polymorphic forms and methods of use thereof
BR112018072168A2 (pt) compostos derivados da pirimidina como inibidores da quinase jak
BR112017023038A2 (pt) imidazopirazinas e pirazolopirimidinas e seu uso como moduladores do receptor ampa
DOP2018000266A (es) 1H-Pirazolo[4,3-b]piridinas como inhibidores de PDE1
CO2021014022A2 (es) Compuestos de 4h-pirrolo[3,2-c]piridin-4-ona
AR071120A1 (es) Derivados de diosmetina, su procedimiento de preparacion, las composiciones farmaceuticas que los contienen y su uso en el tratamiento de las enfermedades venosas cronicas.
BR112017026278A2 (pt) 1,5-di-hidro-4h-pirazolo[3,4-d]pirimidin-4-onas e 1,5-di-hidro-4h-pirazolo[4,3-c]piridin-4-onas como inibidores de pde1
UY37559A (es) Pirazolo[3,4-b]piridina y pirrolo[2,3-b]piridina como inhibidores de la tirosina quinasa de bruton
CL2019001669A1 (es) Pirazolo[3,4-b]piridinas e imidazo[1,5-b]piridazinas como inhibidores de pde1.
CY1109891T1 (el) Παραγωγα ν-(αρυλαλκυλ)-1η-πυρρολοπυριδιν-2-καρβοξαμιδιων, η παρασκευη τους και η εφαρμογη τους σε θεραπειες
MX2020009586A (es) Compuestos de (2-azabiciclo[3.1.0]hexan-2-il)pirazolo[1,5-a]pirimi dina e imidazo[1,2-b]piridazina sustituidos como inhibidores de cinasas trk.
EA201691934A1 (ru) Замещенные 4,5,6,7-тетрагидро-пиразоло[1,5-альфа]пиримидиновые производные и 2,3-дигидро-1h-имидазо[1,2-бета]пиразольные производные в качестве ингибиторов ros1
DK3840832T3 (da) Imidazo[1,2-b]pyridaziner som trk-inhibitorer
MX367772B (es) Derivados de n-(2,3-dihidro-1h-pirrolo[2,3,b]piridin-5-il)-4-quina zolinamina y n-(2,3-dihidro-1h-indol-5-il)-4-quinazolinamina novedosos como inhibidores de perk.
UA117318C2 (uk) ПОХІДНІ 7-(МОРФОЛІНІЛ)-2-(N-ПІПЕРАЗИНІЛ)МЕТИЛТІЄНО[2,3-с]ПІРИДИНУ ЯК ПРОТИРАКОВІ ЛІКУВАЛЬНІ ЗАСОБИ
BR112018004347A2 (pt) derivados de éter cíclico de pirazolo[1,5-a]pirimidina-3-carboxiamida

Legal Events

Date Code Title Description
B25G Requested change of headquarter approved

Owner name: SHANGHAI FOCHON PHARMACEUTICAL CO., LTD. (CN) ; FOCHON PHARMACEUTICALS, LTD. (CN)

B25H Request for change of headquarter rejected

Owner name: SHANGHAI FOCHON PHARMACEUTICAL CO., LTD. (CN) ; FOCHON PHARMACEUTICALS, LTD. (CN)

Free format text: INDEFERIDO O PEDIDO DE ALTERACAO DE SEDE CONTIDO NA PETICAO 870240005936 DE23/01/2024, EM VIRTUDE DA SOLICITACAO JA TER SIDO ATENDIDA PELA PETICAO 870230082563 DE18/09/2023.

B25A Requested transfer of rights approved

Owner name: SHANGHAI FOCHON PHARMACEUTICAL CO., LTD. (CN) ; FOCHON BIOSCIENCES, LTD. (CN)

B25A Requested transfer of rights approved

Owner name: FOCHON BIOSCIENCES, LTD. (CN)